Therapeutics Summaries

Modulation of Lymphocyte Activity
Murphy, Kenneth ; Murphy, Theresa ; Watanabe, Norihiko ; Yang, Jianfei
T-004061

— Background: B and T lymphocyte attenuator (BTLA or CD272) is an inhibitory receptor expressed on T and B cells, dendritic cells and select myeloid cells. BTLA interacts with costimulatory molecule herpesvirus entry mediator (HVEM, Tnfrsf14, ATAR, HVEA, LIGHTR, or TR2). When bound to BTLA, HVEM atten…

Hamster Hybridoma producing Monoclonal Antibody against Murine CD272 (BTLA)
Hurchla, Michelle ; Murphy, Kenneth ; Murphy, Theresa ; Sedy, John
T-004458

— Target: B and T lymphocyte attenuator (BTLA). BTLA is expressed on peripheral lymphocytes, splenic macrophages and select developing B and T cells.Inventors created the monoclonal antibodies by immunizing Armenian hamster or BALB/c background BTLA -/- mice. Hamster monoclonal 6A6 is of the IgG isotype, whereas all murine Abs are IgG1κ. Some of the antibodies recognize the mouse BTLA C57/BL6 allele (6A6, 3F9.C6) and some are panspecific (…

Small molecules targeting KCNQ in ventricular arrhythmia
Cui, Jianmin
T-013554

— Disease indication – Long QT Syndrome (resulting in ventricular arrhythmia, epilepsy, deafness) Drug format – Small molecule Drug class – Lead compounds are repurposed drugs Research stage and preliminary data – Based on in silico screening of KCNQ, the researchers selecte…

Neuroactive steroid anesthetic compounds
Covey, Douglas ; Jiang, Xin
T-004034

— Technology Description Researchers at Washington University have developed a range of steroid anesthetic agents that share known neurosteroid structures but are more potent. These compounds share the basic structure of neurosteroids alphaxalone, allopregnanolone, and ent-androsterone, but the stru…

Low cost, versatile enzymatic synthesis of beta-lactone peptides for antibiotic or serine hydrolase inhibitor drug discovery
Reck, Margaret ; Schaffer, Jason ; Wencewicz, Timothy
T-016508

— Chemists from Washington University have discovered and characterized an enzyme pathway that could be harnessed as an efficient platform to produce peptide beta-lactone libraries for drug discovery. Beta-lactones are a family of molecules with a structure similar to penicillin and therefore could po…

Epigenetic drug targets to treat or prevent osteoarthritis and cartilage degradation
McAlinden, Audrey ; O'Keefe, Regis ; Shen, Jie
T-015627

— A team of researchers at Washington University in St. Louis has identified an epigenetic pathway and two therapeutic targets that could be used to prevent cartilage loss and counteract the mechanism underlying osteoarthritis. The inventors have seen promising results in a mouse model of arthritis us…

Therapy To Prevent Endotracheal Tube Or Catheter-Mediated Tissue Injury
Gelman, Andrew ; Puyo, Carlos
T-015918

— Technology Description Researchers at Washington University in St. Louis have developed a drug combination that can be used to prevent tissue injury resulting from placement of a variety of medical devices including, but not limited to, endotracheal tubes (ETTs) and catheters (bladder catheters). P…

Small molecule inhibitors to prevent tetracycline resistance
Dantas, Gautam ; Forsberg, Kevin ; Gasparrini, Andrew ; Park, Jooyoung ; Tolia, Niraj ; Vogel, Joseph ; Wencewicz, Timothy
T-016593

— Disease indication – Tetracycline resistant infections Drug format – Small molecule (anhydrotetracycline (aTC) or analogs) Drug class – Combination therapy Research stage and Preliminary data Target – Tetracycline destructases (Tet(X), Tet(50), etc) Background &ndas…

Tumor-targeted fusion protein platform for enhanced cancer immunotherapy
Pachynski, Russell
T-015906

— Disease indication – cancer, particularly lung, breast, colon, and prostate cancer or melanoma (cancers where chemerin is down-regulated at the tumor site) Drug format – engineered fusion protein Drug class – first in class Research stage and Preliminary data Target &ndash…

scFv-TR3: TRAIL trimers targeted to mesothelin
Hawkins, William ; Spitzer, Dirk
T-016481

— WUSTL Technology 016481 Technology Description Researchers at Washington University in St. Louis have developed an additional targeting strategy to provide more flexibility and improve the bioactivity of the anticancer therapeutic TR3. This strategy targets TR3 to mesothelin, a tumor biomarker fr…

Mesothelin-TR3: targeted TRAIL trimers with superior anticancer activity
Hawkins, William ; Spitzer, Dirk
T-011885

— WUSTL Technology 011885 Technology Description Researchers at Washington University in St. Louis have developed a strategy to specifically target the anticancer therapeutic TR3 to cancer cells using the mesothelin/MUC16 interaction. Mesothelin is a GPI linked cell surface protein expressed in mes…

Treatments for Wolfram syndrome
Clark, Amy ; Mahadevan, Jana ; Urano, Fumihiko
T-015862

— Technology Description Dr. Fumihiko Urano at Washington University in St. Louis (WUSTL) and colleagues have developed therapeutic strategies to treat Wolfram syndrome. Wolfram syndrome is a rare, life-threating, genetic disorder characterized by insulin-dependent diabetes mellitus, diabetes insipi…

Small molecule inhibitors of G protein activity to treat uveal melanoma, and other cancers and disorders
Blumer, Kendall ; Onken, Michael
T-017344

— Disease indication – Uveal melanoma and other G protein-driven disorders, including other cancers (certain vascular tumors, colon, lung, adenocarcinoma, skin melanoma, thyroid adenoma), cholera and Sturge-Weber Syndrome Drug format – small molecule (FR900359, a bioavailable inhibitor of…

NMDA receptor modulator for neuroprotection after a stroke
Mennerick, Steven ; Sun, Min-Yu ; Taylor, Amanda ; Zorumski, Charles
T-016328

— Disease indication – neuroprotection in stroke/ischemia with potential for treating other neurodegenerative diseases Drug format – neurosteroid Drug class – drug repurposing (25-hydroxycholesterol) Research stage and Preliminary data: In vitro – The inventors demonstrated…

Protein to enhance T cell expansion for CAR-T cell therapy and other adoptive cellular immunotherapy
Chou, Chun ; Egawa, Takeshi
T-016284

— Technology Description Researchers in Prof. Takeshi Egawa’s laboratory have developed a mutant AP4 protein that is designed to reduce the time and expense of ex vivo T cell expansion for adoptive cellular immunotherapy, including CAR-T cell cancer immunotherapy. AP4 is a transcription factor…

Novel kinase inhibitor drugs to treat respiratory disease or breast cancer
Alevy, Yael ; Brett, Thomas ; Holtzman, Michael ; Patel, Anand ; Patel, Dhara ; Romero, Arthur
T-011991

— Disease indications: Drug format: small molecule Drug class: first in class Research stage and Preliminary data: Preclinical development of the lead compound for respiratory disease includes in vitro and in vivo efficacy, selectivity and initial toxicity testing. Preclinical development of the…

Treatment for Age-Related Macular Degeneration (AMD) by Targeting Cholesterol Transport in Macrophages
Apte, Rajendra
T-011268

— Technology Description Researchers in Prof. Rajendra Apte’s laboratory developed novel methods for treating macular degeneration and other eye diseases by targeting a cholesterol transport pathway involved in the formation of new blood vessels. Age-related macular degeneration (AMD) is a lea…

MicroRNA-induced Direct Conversion of Human Adult Fibroblasts into Neurons
Abernathy, Daniel ; Yoo, Andrew
T-017136

— Background: Studying late-onset neurodegenerative disorders using patient-specific neurons is one of the primary goals of precision medicine. The ability to generate human neurons that mimic the neurons of elderly individuals will provide an instrumental platform to model and study adult-onset neuro…

Hydrogels for localized radiotherapy
Azab, Abdel Kareem ; Azab, Feda ; de la Puente Garcia, Maria del Pilar
T-013626

— Background External Beam Radiotherapy (EBR) is commonly used after surgical removal of a tumor (in e.g. a breast-conserving surgery) to control or kill malignant cells. The lack of selectivity due to irradiation of whole or partial organs from outside the body, however, is potentially damaging to t…

Red-Shifted Chromophore Substitution for Optogenetic Applications
Corbo, Joseph ; Enright, Jennifer ; Toomey, Matthew
T-014377

— Optogenetics is one of the most important technological breakthroughs in neuroscience during the past decade, and holds tremendous promise for dissecting the mechanisms of neurologic disease and for treating a range of disorders. Optogenetic actuators are ion channels or pumps that can be regulated …

Combination Artemisinin and Chemiluminescent Photodynamic Therapy for Treatment of Malaria and Cancer
Goldberg, Daniel ; Sigala, Paul
T-015173

— Background: Malaria, mainly caused by Plasmodium falciparum, results in over 200 million clinical cases a year and approximately 430,000 deaths a year. Tropical and sub-tropical countries have a high incidence of malaria cases because Anopheles mosquitoes thrive in warm temperatures and are able to …

Manipulating Tricellular Junction Permeability in Blood Brain Barrier to Treat Brain Tumors
Gong, Yong-feng ; Hou, Jianghui
T-017092

— Background: Brain tumors are the most lethal disease known to mankind with approximately 170,000 annual diagnoses and 13,000 deaths attributed to brain cancer. Glioblastoma, the most common and aggressive, has a median survival of approximately 18 months. Chemotherapeutic agents have been approved b…

Antibody to SPRR3
Ladenson, Jack ; Young, Pampee
T-004462

— Analyte: Small proline rich protein 3 (gene SPRR3) Antibody codes: 3E9.1 (4587), 4G3.1 (4563), and 2F10.2 (4604) Publications:

Itaconate Immunomodulatory Properties-Ischemia Reperfusion
Artyomov, Maxim ; Lampropoulou, Vasiliki "Vicky"
T-016181

— Technology Summary: Approximately 1.3 million individuals each year in USA alone are affected by ischemia-reperfusion injuries. A substantial portion of such injuries is the result of macrophage-mediated inflammation. There are some conventional methods for treating macrophage-mediated inflammation,…

Lysosomal Enzyme GlcNAc-1-phosphotransferase with Enhanced Ability to Phosphorylate Lysosomal Enzymes
Doray, Balraj ; Kornfeld, Stuart ; Lee, Wang ; Liu, Lin
T-016569

— Lysosomal storage disorders result in severe, multi-system dysfunction and frequently, early death. Currently, a number of lysosomal storage disorders are treated with enzyme replacement therapy (ERT), which requires periodic infusions of the deficient enzyme. However, in a number of instances the…

Therapeutic Approach for Huntington’s Disease (HD)
Kim, Albert ; Yano, Hiroko
T-016079

— Dr. Hiroko Yano and Dr. Albert Kim, and their research teams at the Washington University School of Medicine in St. Louis developed and extensively evaluated a novel therapeutic approach using DNMT inhibitors to treat Huntington’s Disease (HD) and other neurodegenerative disorders. Currently D…

Agonistic Anti-CD40 Monoclonal Antibodies
Klechevsky, Eynav
T-015344

— The monoclonal antibodies developed are agaonistic monoclonal antibodies. These antibodies can help in enhancing the immune system by activating dendritic cell subsets. Furthermore, these antibodies are unique, as they can activate Dendritic cells without the need for cross-linking the receptor.

Quit Helpers
Colditz, Graham ; McQueen, Amy ; Sumner, Walton
T-014916

— Quit Helpers is an interactive web-based tool to recommend pharmacotherapy to smokers based on medical and personal factors. Although general information about cessation aids is abundant, Quit Helpers automates the process of identifying a specific cessation aid or combination of aids for individua…

Enantiomeric16-ketosteroids and Related Tetracyclic & Tricyclic Analogues with Neuronal Actions
Covey, Douglas
T-011272

— Neurosteroids are of great interest because of their ability to alter brain function. Compounds of the type disclosed here have potential to be new drugs useful for causing anesthesia and treating depression, anxiety, sleep disorders, seizures.

Treatment for Centrally Mediated Itching
Chen, Zhoufeng ; Sun, Yan Gang
T-006757

— Background: Severe itch (or pruritus) is associated with multiple diseases such as liver disease, non-Hodgkin’s lymphoma, psoriasis, and common eczema and is also a side effect of many treatments including analgesics (like morphine) and renal dialysis. Chronic pruritus is a top reason for derm…

Intraocular Artificial Lenses
Ravi, V. Nathan
T-006771

— The present hydrogel technology can be used as a lens replacement material for the permanent treatment of cataracts and presbyopia as well as a vitreous substitute. This co-polymeric hydrogel system can be reversibly converted between a hydrogel in the oxidized state and a solution in the reduced st…

Methods to Treat Vasodilatory Septic Shock
Boyle, Walter
T-007528

— Background: Vasodilatory shock, a reduction in effective blood circulation, occurs when endogenous vasoconstrictor mechanisms fail as a result of an often lethal combination of severe infections. Sepsis, as one of the causes, alone affects 1 million people resulting in more than 258,000 deaths each …

Modulation of the DLK/JNK Pathway as a Method for Inhibiting Axonal Degeneration
DiAntonio, Aaron ; Milbrandt, Jeffrey ; Miller, Bradley ; Press, Craig
T-008422

— Background: Axonal degeneration is a feature commonly associated with many neuropathological conditions including response to injury, exposure to neurotoxins, hereditary neuropathies, glaucoma, and neurodegenerative diseases. The degenerative process is active when neuronal insults trigger a self-de…

Graft-vs-Host Disease Prevention during Stem Cell Transplantation
Albring, Jorn ; Murphy, Kenneth ; Sandau, Michelle
T-009478

— Background: Allogeneic hematopoietic stem-cell transplantation (aHSCT) from a healthy donor can cure a variety of blood cell disorders including leukemia, multiple myeloma, and some types of lymphoma. This has resulted in an increasing number of transplants, surpassing 8,000 a year in the US alone. …

MOR1D Mediates Opioid and Liver Disease-Induced Itch via GRPR
Chen, Zhoufeng ; Liu, Xianyu
T-011473

— Background: Opioids, such as morphine, are used in pain management and have significant analgesic effects. However a common side effect of morphine is severe itching. Currently, morphine-induced itch is treated with antagonists against the mu opioid receptor. While these antagonists reduce itch, the…

Phospholipase A2 Epsilon
Gross, Richard ; Jenkins, Christopher
T-004045

— This features an enzymatic function for a protein so that Washington University can obtain composition of matter rights and use rights for screening for inhibitors. This can be used for weight loss, diabetes, treatment of obesity and associated lipotoxicity, body sculpting, heart disease, stroke a…

Modulation of Lymphocyte Activity
Murphy, Kenneth ; Murphy, Theresa ; Watanabe, Norihiko ; Yang, Jianfei
T-004061

— Background: B and T lymphocyte attenuator (BTLA or CD272) is an inhibitory receptor expressed on T and B cells, dendritic cells and select myeloid cells. BTLA interacts with costimulatory molecule herpesvirus entry mediator (HVEM, Tnfrsf14, ATAR, HVEA, LIGHTR, or TR2). When bound to BTLA, HVEM atten…

FES Recovery of Neurologic Function and Regeneration
McDonald, John W.
T-003694

— Washington University inventors have found that FES enhances spontaneous neurological recovery. This can be used in the development of FES systems for regeneration of recovery of function.

Method of increasing chemotherapy sensitivity in leukemia using BET inhibitor
Mitra, Robi ; Moudgil, Arnav ; Wilkinson, Michael Nathaniel
T-019486

— Technology Description Researchers in Robi Mitra’s lab at Washington University in St. Louis have developed a method to increase the sensitivity of leukemias to chemotherapy by pre-treatment with a BET inhibitor. BET inhibitors convert stem-like leukemia cells to a more differentiated state …

NRF2 inhibitors as cancer therapeutics
Bowman, Brittany ; Dolle, Roland "Ron" ; Lapak, Kyle ; Major, Michael "Ben" ; Medcalf, Matthew
T-019534

— Disease indication – Diseases related to oxidative stress, including cancer, autoimmune disease, and Toxoplasma infection Drug format – Small molecule Drug class – Best-in-class Research stage and preliminary data – The researchers have synthesized a series of pyrimethamin…

Targeting hepatic arginine metabolism for treatment of metabolic diseases
DeBosch, Brian ; Higgins, Cassandra ; Mayer, Allyson ; Zhang, Yiming
T-017490

— Background Over 30% of adults in the world are overweight or obese. Lifestyle management has proven to be impractical and ineffective in real-life settings and there are no current treatments available for metabolic disease. Technology Summary Pharmacological or genetic activation of the Arginine…

Optimized MHC-independent T cell receptors as a CAR-T alternative
Chang, Ju Fang ; Singh, Nathan
T-019636

— Technology Description Researchers in Nathan Singh’s lab at Washington University have developed a construct for cell therapy that combines facets of existing CAR-T therapy and the endogenous T cell receptor (TCR) to better regulate adoptive cell activation. Unlike the traditional TCR, this …

Antibody blocking IL-12 and IL-23 receptors to treat inflammatory diseases
Colonna, Marco ; Secca da Silva, Cristiane
T-019316

— Disease indication – Autoimmune diseases (plaque psoriasis, psoriatic arthritis, Crohn’s disease) Drug format – Monoclonal antibody Drug class – First-in-class Research stage and preliminary data – Researchers have stimulated human ILC3s with IL-23 in vitro, with and…

S1P1-targeted PET tracers
Liu, Hui ; Rosenberg, Adam ; Tu, Zhude "Will" ; Yue, Xuyi
T-016151

— Technology Description Researchers at Washington University in St. Louis have developed sphingosine 1-phosphate receptor 1 (S1P1)-specific PET tracers. Sphingosine 1-phosphate receptors are G-protein coupled receptors, with five subtypes denoted S1P1-5, that have key functions in immune, inflammat…

Control of Dietary and Microbial Exposure in Early Life as a Novel Approach to Target Allergy Development in Infants
Knoop, Kathryn ; McDonald, Keely ; Newberry, Rodney
T-016480

— Background: The frequency of allergic disorders has been rapidly increasing in children in Western societies. Previous studies have shown reduced allergic outcomes in at-risk children upon breast feeding with complementary introduction of food allergens combined with limited oral antibiotic exposure…

microRNA biomarker and drug target for ALS and other motor neuron diseases
Dougherty, Joseph ; Hoye, Mariah ; Hyman, Theodore ; Koval, Erica ; Miller, Timothy
T-015167

— Prof. Timothy Miller and colleagues have identified a motor neuron-specific, drug responsive microRNA (miR-218) that reflects the pathology of amyotrophic lateral sclerosis (ALS). This biomarker could be a target for therapeutic intervention or a proxy for motor neuron health and survival, including…

Obligate Heterotetrameric Pairs of Cre Recombinase Mutants for Efficient Recombination at Asymmetric Sites
Corbo, Joseph ; Havranek, James ; Mitra, Robi ; Myers, Connie ; Qi, Zongtai ; Zhang, Chi
T-015523

— Background: The function of enzymes involved in homologous recombination can be exploited in the field of genetic engineering in order to generate mutations of interest. However, this machinery is not functionally efficient in post mitotic or terminally differentiated cells. Viral gene therapy techn…

Combination therapy for malignant peripheral nerve sheath tumors
Amin, Neha ; Borcherding, Dana ; Hirbe, Angela
T-020000

— Technology Description Researchers in Angela Hirbe’s lab at Washington University have developed a method of treating malignant peripheral nerve sheath tumors (MPNSTs) with a combination of inhibitors. The most effective therapy is to combine an inhibitor of TYK2 with a MEK inhibitor. MPNST…

Technique to reduce juxta-anastomotic stenosis development in AV fistulae
Shenoy, Surendra
T-010339

— Technology Description Researchers at Washington University in St. Louis have developed a technique for arteriovenous fistula creation that reduces the incidence of juxta-anastomotic stenosis, which often leads to graft failure. The procedure involves clamping closed one end of the graft and attac…

Optimized MHC-independent T cell receptors as a CAR-T alternative
Chang, Ju Fang ; Singh, Nathan
T-019636

— Technology Description Researchers in Nathan Singh’s lab at Washington University have developed a construct for cell therapy that combines facets of existing CAR-T therapy and the endogenous T cell receptor (TCR) to better regulate adoptive cell activation. Unlike the traditional TCR, this …

NRF2 inhibitors as cancer therapeutics
Bowman, Brittany ; Dolle, Roland "Ron" ; Lapak, Kyle ; Major, Michael "Ben" ; Medcalf, Matthew
T-019534

— Disease indication – Diseases related to oxidative stress, including cancer, autoimmune disease, and Toxoplasma infection Drug format – Small molecule Drug class – Best-in-class Research stage and preliminary data – The researchers have synthesized a series of pyrimethamin…

Antibody blocking IL-12 and IL-23 receptors to treat inflammatory diseases
Colonna, Marco ; Secca da Silva, Cristiane
T-019316

— Disease indication – Autoimmune diseases (plaque psoriasis, psoriatic arthritis, Crohn’s disease) Drug format – Monoclonal antibody Drug class – First-in-class Research stage and preliminary data – Researchers have stimulated human ILC3s with IL-23 in vitro, with and…

JAK inhibitor as conditioning agent for allogeneic hematopoietic stem cell transplantation
DiPersio, John ; Persaud, Stephen "Steve"
T-019132

— Technology Description Researchers at Washington University in St. Louis have developed an improved process for conditioning patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) using JAK inhibitors. Commonly used to treat autoimmune diseases like rheumatoid arthritis, JAK inh…

Chimeric antigen receptor dendritic cells
DeSelm, Carl
T-019199

— Technology Description Researchers at Washington University in St. Louis have developed a genetic method to produce chimeric antigen receptor dendritic cells (CAR-DCs) for the treatment of solid tumors. The team generated a CAR that drives differentiation of cDC1s and mediates tumor-specific uptak…

Therapeutic targeting of LDL in ALS
Kreple, Collin ; Miller, Timothy ; Nielsen, Susan ; Racette, Brad
T-020021

— Technology Description Researchers in Brad Racette and Tim Miller’s labs at Washington University have developed a therapeutic strategy for treating ALS by using statins to lower LDL. Statins were successful at prolonging both survival and time with a normal gait. The researchers identif…

Mutant PDGF-B as a VEGFR inhibitor
Imoukhuede, Princess
T-018996

— Technology Description Researchers in the Imoukhuede lab at Washington University have developed a library of mutant PDGF-B proteins to develop more effective VEGF pathway inhibitors. As PDGF-B also binds to VEGF receptors, a mutant form can be used to block VEGF binding and stop tumor angiogenesi…

Targeting TPL2 in RAS-mutated cancers
Dodhiawala, Paarth ; Lim, Kian-Huat
T-019493

— Technology Description Researchers in Kian-Huat Lim’s lab at Washington University have developed a therapeutic strategy to target TPL2 in RAS-mutated cancers, which should work synergistically with chemotherapy and radiation. As TPL2 (MAP3K8) is necessary for upstream activation of both MAP…

SARS-CoV-2 neutralizing antibodies with distinct epitopes effective against multiple variants
Ellebedy, Ali
T-019707

— Disease indication – SARS-CoV-2 infection (COVID-19) Drug format Drug class – Best-in-class Research stage and Preliminary data – The inventors have developed and characterized these antibodies, creating a chimeric version with a human IgG backbone for SARS2-38. The antibodies have …

A novel modulator of tumor angiogenesis and anti-tumor immunity
Choi, Kyunghee ; Kabir, Ashraf Ul ; Krchma, Karen
T-019294

— Technology Description Researchers in Kyunghee Choi’s lab at Washington University in St. Louis have identified a novel target, Myct1, that modulates tumor angiogenesis and anti-tumor immune response. Myct1 inhibition with siRNA blocks angiogenesis and promotes infiltration of cytotoxic T ly…

SARS-CoV-2 neutralizing antibody effective against all variants
Adams, Lucas ; Diamond, Michael ; Fremont, Daved ; VanBlargan, Laura
T-019791

— Disease indication – SARS-CoV-2 infection (COVID-19) Drug format – Chimeric monoclonal antibody Drug class – Best-in-class Research stage and Preliminary data – The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. T…

TREM2 blockade as an adjuvant for checkpoint inhibitors
Colonna, Marco
T-019371

— Disease indication – In combination with anti-PD-1 therapy for cancer. Anti-PD-1 therapy is currently approved for: Drug format – Monoclonal antibody Drug class – First-in-class Target – TREM2 Research stage and preliminary data – The inventors performed initia…

An alternative approach in antimalarial drug design
Djuranovic, Sergej ; Erath, Jessey Lee ; Pavlovic Djuranovic, Slavica
T-018688

— Technology Description Researchers in Sergei Djuranovic’s lab at Washington University have developed polybasic peptides and polymers to block Plasmodium falciparum adhesion as a treatment for malaria. These therapeutics reduce parasite infection of human cells, making this a promising alter…

Method of increasing chemotherapy sensitivity in leukemia using BET inhibitor
Mitra, Robi ; Moudgil, Arnav ; Wilkinson, Michael Nathaniel
T-019486

— Technology Description Researchers in Robi Mitra’s lab at Washington University in St. Louis have developed a method to increase the sensitivity of leukemias to chemotherapy by pre-treatment with a BET inhibitor. BET inhibitors convert stem-like leukemia cells to a more differentiated state …

Fusion protein for treating multiple strains of Venezuelan equine encephalitis virus
Diamond, Michael ; Fremont, Daved ; Kafai, Natasha ; Kim, Arthur ; Ma, Hongming ; Thackray, Larissa
T-019414

— Disease indication – Venezuelan equine encephalitis virus (VEEV) infection, either naturally-arising and as a result of bioterrorism Drug format – Biologic (soluble receptor fusion protein) Drug class – First-in-class Mode of action – This soluble fusion protein contains domain …

PI3K inhibitors to treat Cytokine Release Syndrome
Amatya, Parmeshwar ; Carter, Alun ; Cooper, Matthew ; DiPersio, John
T-019429

— Technology Description A team of researchers, led by John DiPersio and Matthew Cooper at Washington University in St. Louis, have identified a small molecule kinase inhibitor capable of mitigating cytokine release syndrome following CAR-T cell therapy. PI3K inhibitors can suppress production of IL-…

An Intradermal Method for the Treatment of Hair Loss and Alopecia
Feng, Jing ; Hu, Hongzhen ; Luo, Jialie ; Yang, Pu
T-017716

— Technology Description: A team of researchers, led by Hongzhen Hu, at Washington University in St. Louis has developed a method of treating hair loss and alopecia by intradermal injection targeting TRPV4 activation. Using a small molecule TRPV4 agonist, a single intradermal injection is sufficient…

Interferon-gamma treatment to improve efficacy of hematopoietic stem cell transplantation for AML and other cancer
Christopher, Matthew ; DiPersio, John ; Ley, Timothy ; Petti, Allegra ; Rettig, Michael
T-018954

— Technology Description Researchers at Washington University in St. Louis have discovered that interferon-gamma treatment could potentially prevent relapse after hematopoietic stem cell transplantation (HCT) treatment by making the cancer cells more visible to the donor immune cells. This technolog…

Therapeutic targets for atopic dermatitis
Kim, Brian ; Wang, Fang
T-019333

— Researchers at Washington University’s Center for the Study of Itch & Sensory Disorders have discovered a novel histamine-independent pathway that could be targeted to treat atopic dermatitis. Atopic dermatitis (AD) is a chronic inflammatory skin disease that presents with itch as its mos…

Treatment for chronic migraines
Cao, Yu-Qing ; Cloud, Megan ; Hu, Rong ; Zhang, Jintao ; Zhang, Zhiyu
T-018942

— Technology Description Researchers at Washington University in St. Louis (WUSTL) have developed two methods for treating chronic migraine and post-traumatic headache. Chronic migraine and post-traumatic headache are highly prevalent and debilitating with limited treatment options. Further, for m…

Stimulating Innate Immune Cells for Cancer Therapy or Vaccine Adjuvants
Barrow, Alexander ; Colonna, Marco
T-016924

— Technology Description Researchers in Prof. Marco Colonna’s laboratory have identified a receptor-ligand interaction that could be harnessed to activate the innate immune system to treat cancer or enhance the response to vaccines for infectious disease. Specifically, platelet-derived growth f…

Method to generate functionally mature, stem-cell derived, beta cells
Millman, Jeffrey ; Velazco-Cruz, Leonardo
T-019270

— Technology Description Researchers at Washington University in St. Louis have developed an improved method to differentiate stem-cells into functionally mature, insulin-secreting beta cells (SC-beta cells). Pancreatic beta cells play an important role in controlling blood glucose levels as they se…

miRNA mimics to treat metabolic disease
Gong, Yong-feng ; Hou, Jianghui
T-017930

— Disease indication: metabolic disorders including insulin resistance and diabetic nephropathy Drug format: chemically modified synthetic microRNA (miRNA) Drug class: first-in-class for metabolic disease Research stage and Preliminary data: Target: miR-29 mimics can increase the gene expressio…

Device for diabetes cell replacement therapy
Millman, Jeffrey ; Song, Jiwon
T-016681

— Technology Description Researchers at Washington University in St. Louis have developed a 3D-printed device for the subcutaneous transplantation of stem cell-derived beta (SC-beta) cells for diabetes cell replacement therapy. Diabetes mellitus, a disease characterized by loss of blood glucose cont…

Compound to treat alcohol use disorder
Covey, Douglas ; Mennerick, Steven
T-019232

— Technology Description Researchers at Washington University in St. Louis have developed new compounds that may be used to treat alcohol use disorder (AUD). AUD, a common condition that takes a high personal and public health toll, is characterized by severe problems with drinking- sufferers may co…

Method to create designer stem cells for safer, more effective therapeutics
Guilak, Farshid
T-018758

— Technology Description Researchers at Washington University in St. Louis have developed a method to create designer stem cells which provide a safer, more effective cell therapy approach to treating disease. Cell-based regenerative therapies could potentially be used to treat many diseases and res…

Antibiotic-sparing small molecule therapy for urinary tract infection and other Gram-negative pathogens
Dodson, Karen ; Hultgren, Scott ; Omattage, Natalie ; Pinkner, Jerome ; Yuan, Peng
T-018046

— Technology Description Researchers in Prof. Scott Hultgren’s laboratory have discovered an antibiotic-sparing method for treating infections from E. coli and other Gram-negative bacteria. This approach is designed to block pathogens from colonizing their host by using small molecule inhibito…

Sigma-1 targeted PET tracers
Mach, Robert ; Tu, Zhude "Will" ; Wang, Wei
T-010394

— Technology Description Researchers at Washington University in St. Louis and their colleagues have developed positron emission tomography (PET) tracers with high affinity for sigma-1 receptors. Sigma receptors have two subtypes, sigma-1 and sigma-2. Sigma-1 has high expression in the limbic and mo…

S1P1-targeted PET tracers
Liu, Hui ; Rosenberg, Adam ; Tu, Zhude "Will" ; Yue, Xuyi
T-016151

— Technology Description Researchers at Washington University in St. Louis have developed sphingosine 1-phosphate receptor 1 (S1P1)-specific PET tracers. Sphingosine 1-phosphate receptors are G-protein coupled receptors, with five subtypes denoted S1P1-5, that have key functions in immune, inflammat…

Radium Chelation For Targeted Alpha Particle Therapy
Abou, Diane ; Thorek, Daniel
T-019039

— Technology Description Researchers at Washington University in St. Louis have developed a method to chelate radium-223 and increase its utility in targeted alpha-particle therapy (TAT). TAT aims to deliver cytotoxic alpha-particles to cancer cells. Radium-223 is an alpha particle emitting isotope …

Ion Channel Blockade of Radium-223 Gut Uptake
Abou, Diane ; Thorek, Daniel
T-018999

— Technology Description Researchers at Washington University in St. Louis have developed a method to reduce gut uptake of Radium-223 and improve its targeting to metastasized bone cancer. Prostate cancer is the most common cancer among men and a leading cause of cancer-related mortality. Prostate c…

Chimeric Artificial Interference RNA (aiRNA) for RNAi-based cancer therapy
Wang, Xiaowei
T-014021

— Technology Description In search of more effective cancer treatments, inventors in Dr. Xiaowei Wang’s lab at Washington University School of Medicine have developed artificial interference RNA (aiRNA). aiRNA is a patented chimeric RNAi that combines the multi-target abilities of miRNAs and t…

Use of ent-allopregnanolone to treat glaucoma
Covey, Douglas ; Izumi, Yukitoshi ; Zorumski, Charles
T-018940

— Technology Description Researchers from Washington University in St. Louis and colleagues have identified ent-allopregnanolone (ent-AlloP) as a potential therapeutic to treat glaucoma. Glaucoma, the leading cause of irreversible blindness, results from damage to the retinal ganglion cells (RGSs) t…

Vaccines and antibodies against malaria and other parasitic diseases in humans and animals
Jimah, John ; Tolia, Niraj
T-016150

— Technology Description Researchers in Prof. Niraj Tolia’s laboratory have exploited structure-based vaccine design to develop immunogenic compositions and neutralizing antibodies that could protect against malaria and a range of other parasitic diseases that affect humans, livestock and comp…

Drug target and biomarker for multiple sclerosis
Klein, Robyn ; Williams, Jessica
T-017623

— Technology Description Researchers in Prof. Robyn Klein’s laboratory have discovered that interferon lambda (IFN-λ) is a potential target for treating multiple sclerosis (MS), particularly secondary progressive MS (SPMS). Most patients with MS present with relapsing remitting MS (RRM…

Vaccine to prevent catheter-associated urinary tract infection
Caparon, Michael ; Flores-Mireles, Ana ; Hultgren, Scott ; Pinkner, Jerome
T-013965

— Technology Description Researchers at Washington University in St. Louis have developed a vaccine strategy to prevent catheter-associated urinary tract infections (CAUTIs). CAUTIs are the most common cause of hospital-acquired infections. Many of these are caused by Enterococcus bacteria. CAUTIs a…

Target and small molecule drugs to selectively neutralize bacteria in urinary tract infections
Henderson, Jeffrey P.
T-018628

— Technology Description Researchers in Prof. Jeffrey Henderson’s laboratory have discovered a drug target and a class of small molecule candidates that could be used to selectively prevent pathogenic enterobacteria from causing diseases such as urinary tract infections (UTIs). Currently, UTI…

Cytokine therapy for juvenile dermatomyositis and other autoimmune diseases
Alinger, Joshua ; French, Anthony ; Throm, Allison
T-018911

— Technology Description Researchers in Prof. Anthony French’s laboratory have discovered a signaling mechanism associated with juvenile dermatomyositis (JDM) that could potentially be targeted with cytokine-based therapies to treat JDM as well as other autoimmune disorders. This therapeutic a…

Zika Oncolytic Virus to Treat Glioblastoma and Other Solid Tumors
Chheda, Milan ; Diamond, Michael ; Gorman, Matthew
T-017429

— Disease indication: Glioblastoma, Lung Cancer, Breast Cancer and other Cancers with Cancer Stem Cells Drug format: Oncolytic Virus Drug class: First-in class Research stage and Preliminary data: 1st Generation – Zika Virus (ZIKV) 2nd Generation – Attenuated ZIKV (E218A) Figur…

NanoTCE: a nanoparticle antibody system for immunotherapy against heterogeneous multiple myeloma
Alhallak, Kinan ; Azab, Abdel Kareem
T-018892

— Disease indication – multiple myeloma Drug format – antibodies conjugated to nanoparticles for T-cell immunotherapy Drug class – improved delivery platform Research stage and Preliminary data: In vivo: In vitro proof of concept – in a MM cell line: NanoMuTEs and NanoTC…

Potent, locally-acting chemokine binding proteins to protect organ transplants and treat ischemic or inflammatory diseases
Fremont, Daved ; Lu, Yun Hsuan ; Lubman, Olga
T-017443

— Researchers in Prof. Daved Fremont’s laboratory have identified two potent, soluble proteins that could prevent damage to transplanted organs and potentially treat other autoimmune and inflammatory diseases by evading the immune response instigated by chemokines. In organ transplants, chemoki…

Therapy to treat and prevent respiratory disease in pre-term and at-risk neonates
Morley, Sharon "Celeste" ; Todd, Elizabeth (Betsy)
T-017434

— Technology Description Researchers in Prof. S. Celeste Morley’s laboratory have developed a long-lasting prophylactic therapy that could protect pre-term and at-risk infants from pneumonia, respiratory distress and bronchopulmonary dysplasia. Neonates born prematurely are at increased risk f…

Engineered Adenovirus Vector for Efficient Dendritic Cell Antigen Loading in Cancer Immunotherapy
Curiel, David
T-011681

— Disease indication – Cancer Drug format – Adenoviral vector for immunotherapy/dendritic cell therapy Drug class – Improvement Research stage and Preliminary data: Target – Carbohydrate biomarkers of cancer Background: Dendritic cells (DCs) are potent antigen presenting cell…

Targeting hepatic arginine metabolism for treatment of metabolic diseases
DeBosch, Brian ; Higgins, Cassandra ; Mayer, Allyson ; Zhang, Yiming
T-017490

— Background Over 30% of adults in the world are overweight or obese. Lifestyle management has proven to be impractical and ineffective in real-life settings and there are no current treatments available for metabolic disease. Technology Summary Pharmacological or genetic activation of the Arginine…

Targeting hepatic arginine metabolism for treatment of metabolic diseases
DeBosch, Brian ; Higgins, Cassandra ; Mayer, Allyson ; Zhang, Yiming
T-017417

— Background Over 30% of adults in the world are overweight or obese. Lifestyle management has proven to be impractical and ineffective in real-life settings and there are no current treatments available for metabolic disease. Technology Summary Pharmacological or genetic activation of the Arginine…

Targeting CD5+ Dendritic Cell in Skin for the Treatment of Chronic Diseases
Klechevsky, Eynav
T-016609

— Background Dendritic cells (DCs) are antigen-presenting cells that are essential to the adaptability of the immune system. Several subsets of DCs have been identified in tissues that interface with the environment (e.g. skin, mucosal lining). While the role of specific DC subsets are unknown, DCs p…

Biological and Biochemical Production of Enantiopure L-Piperazic Acid
Hu, Yifei ; Van Dyke-Blodgett, Joshua
T-017073

— Background: Compounds containing piperazic acid (Piz), a nonproteinogenic amino acid, are of significant interest for drug discovery. Peptidic compounds incorporating Piz as a building block include antibacterial, antiviral, immunomodulatory and anticancer drug leads, and all naturally-occurring Pi…

Design and Development of Organomedicinals for Imaging and Treatment of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (FTD)
Guruswami, Sundaram ; Sharma, Vijay ; Sivapackiam, Jothilingam
T-016665

— Background Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…

Multifunctional chemical agents for metal chelation, positron emission tomography (PET) imaging, fluorescence imaging, and amyloid plaque clearance in Alzheimer’s disease
Mirica, Liviu ; Schultz, Jason ; Sharma, Anuj
T-013190

— Alzheimer’s disease (AD) is characterized by the deposition of amyloid plaques containing the amyloid beta (Aβ) peptide. Currently, no treatment is available for AD. Metal ion interactions of the Aβ peptide are believed to help formation of toxic aggregates. Developing chemical compo…

Imaging and treatment of pathophysiologic conditions by Cerenkov Radiation
Achilefu, Samuel ; Kotagiri, Nalinikanth
T-013974

— Background: Around 1 million patients receive radiation therapy every year with an estimated cost of $2,000 per treatment. The market demands technologies that can provide efficacious therapeutics and diagnostic imaging while minimizing harmful side effects. Photodynamic therapy can simultaneously s…

microRNA biomarker and drug target for ALS and other motor neuron diseases
Dougherty, Joseph ; Hoye, Mariah ; Hyman, Theodore ; Koval, Erica ; Miller, Timothy
T-015167

— Prof. Timothy Miller and colleagues have identified a motor neuron-specific, drug responsive microRNA (miR-218) that reflects the pathology of amyotrophic lateral sclerosis (ALS). This biomarker could be a target for therapeutic intervention or a proxy for motor neuron health and survival, including…

New Method to Produce a DNA Mutation Library
Alvarado, David ; Dobbs, Matthew ; Gurnett, Christina ; Haller, Gabriel
T-015343

— Background: A DNA point mutation is a single nucleotide base substitution, insertion, or deletion in a gene sequence. Point mutations are responsible for several diseases including cystic fibrosis, sickle-cell disease, polycystic kidney disease, microcephaly, and Crohn’s disease. The study on …

Obligate Heterotetrameric Pairs of Cre Recombinase Mutants for Efficient Recombination at Asymmetric Sites
Corbo, Joseph ; Havranek, James ; Mitra, Robi ; Myers, Connie ; Qi, Zongtai ; Zhang, Chi
T-015523

— Background: The function of enzymes involved in homologous recombination can be exploited in the field of genetic engineering in order to generate mutations of interest. However, this machinery is not functionally efficient in post mitotic or terminally differentiated cells. Viral gene therapy techn…

Nano-CaCO3
Achilefu, Samuel ; Biswas, Pratim ; Raliya, Ramesh ; Som, Avik
T-015910

— Background: Physiological pH changes consistently affect millions of people worldwide. A slight variation in physiological pH exposes the body to various health risks, ranging from common heartburn to the formation of malignant tumors. Conventional methods for buffering pH are accomplished through a…

Control of Dietary and Microbial Exposure in Early Life as a Novel Approach to Target Allergy Development in Infants
Knoop, Kathryn ; McDonald, Keely ; Newberry, Rodney
T-016480

— Background: The frequency of allergic disorders has been rapidly increasing in children in Western societies. Previous studies have shown reduced allergic outcomes in at-risk children upon breast feeding with complementary introduction of food allergens combined with limited oral antibiotic exposure…

Styryl Heteroaromatic Ring Containing Analogues for Alpha-Synuclein
Kotzbauer, Paul ; Li, Junfeng ; Tu, Zhude "Will" ; Yue, Xuyi
T-014558

— Compounds with high affinity for aggregated alpha-synuclein, after radiolabeling with C-11 or F-18, 1- 125, 1-123 and Br-76, could be used as PET tracers to measure the level and distribution of aggregated alpha-synuclein in patients with Parkinson’s disease and related diseases such as DLB…

Drugs to supplement microglial metabolism during treatment of Alzheimer’s disease
Colonna, Marco ; Ulland, Tyler
T-017401

— Background: Alzheimer’s disease (AD) is the 6th leading cause of death in the United States, and yet causation of the disease is poorly understood and targets for therapeutic intervention are still being identified. Recently, mutations in the immune receptor TREM2 have been found to be strongl…

Monoclonal Antibodies Against Zika Virus and Purified Zika E Protein
Diamond, Michael ; Fernandez, Estefania ; Fremont, Daved ; Nelson, Christopher ; Platt, Derek ; Zhao, Haiyan
T-016168

— To generate a panel of antibodies against ZIKV, we serially infected Irf3/ mice 30 days apart with ZIKV MR-766 (Uganda, 1947) and ZIKV H/PF/2013 (French Polynesia, 2013). Irf3/ mice were used instead of wild-type (WT) mice, because ZIKV strains are deficient in evading type I interferon-mediated imm…

Pro-drug Nanoparticle Technology (Used to be: Rational Design and Synthesis of Photo chemically stable Fumagillin Conjugates)
Lanza, Gregory ; Pan, Dipanjan ; Wickline, Samuel
T-007663

— Background: Targeted nanoparticles have been shown to have high potential in the detection and characterization of various pathologies based on unique profiles of cell surface markers, as well as the delivery of therapeutic compounds. Liposomes, micelles, emulsions and other lipid-based particles ha…

Compositions for targeting pathologic cells and tissues
Achilefu, Samuel ; Liang, Kexian ; Shen, Duanwen ; Tang, Rui ; Xu, Baogang
T-015230

— Background: Almost 1.7 million new cancer cases are diagnosed in the US each year. Pancreatic cancer is particularly lethal, with an estimated 38,000 deaths in 2013 alone and a 5-year survival rate of 5%. Despite advances in noninvasive imaging modalities, the current gold standard consisting of …

Inflammatory bowel disease biomarkers and therapeutic target
Kaiko, Gerard ; Liu, Ta-Chiang ; Stappenbeck, Thaddeus
T-017071

— Plasminogen activator inhibitor-1 (PAI-1) has been identified as a specific biomarker that is significantly elevated in patients with inflammatory bowel disease (IBD) and is correlated with disease severity. It could be used to both diagnose the disease (including ulcerative colitis and colonic Croh…

Anti-fungal treatment and companion diagnostic for Crohn’s Disease
Jain, Umang ; Stappenbeck, Thaddeus
T-019293

— Technology Description: Researchers at Washington University in St. Louis have identified a new avenue for treatment of non-healing ulcers in patients with Crohn’s disease by targeting Debaryomyces hansenii. While the cause of Crohn’s disease is unknown, the fungus D. hansenii colonize…

Peptides responsible for Type 1 diabetes
Lichti, Cheryl ; Unanue, Emil ; Wan, Xiaoxiao
T-018626

— Technology Description: Researchers in the lab of Emil Unanue at Washington University have discovered a panel of peptides responsible for autoimmune activation in Type 1 diabetes and potentially capable of diagnosing T1D at an early stage. These peptide fragments of insulin are found circulating …

CCR2-targeted cancer nanoimmunotherapy
Lim, Kian-Huat ; Liu, Yongjian ; Zhang, Xiaohui
T-019463

— Disease indication – Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide Drug class – First-in-class Target – CCR2, the receptor for CCL2 Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…

Inflammatory bowel disease biomarkers and therapeutic target
Kaiko, Gerard ; Liu, Ta-Chiang ; Stappenbeck, Thaddeus
T-017071

— Plasminogen activator inhibitor-1 (PAI-1) has been identified as a specific biomarker that is significantly elevated in patients with inflammatory bowel disease (IBD) and is correlated with disease severity. It could be used to both diagnose the disease (including ulcerative colitis and colonic Croh…

Long non-coding RNA as cancer biomarker and drug target
Cabanski, Christopher ; Fields, Ryan ; Maher, Christopher ; Silva-Fisher, Jessica
T-018788

— Technology Description Researchers in Prof. Christopher Maher’s research program (in conjunction with collaborator Ryan Fields) discovered that RAMS11 (RNA Associated with Metastasis 11), a novel long non-coding RNA, (i) promotes metastatic disease, (ii) confers resistance to topoisomerase i…

Targeted liposome drug delivery system to improve multiple myeloma treatment
Azab, Abdel Kareem ; Federico, Cinzia
T-019089

— Technology Description Researchers in Prof. Kareem Azab’s laboratory have developed a liposome drug delivery vehicle to improve efficacy and reduce side effects of multiple myeloma treatment. This system is designed to target compounds to the bone marrow microenvironment (BMME) and simultane…

Synthetic Dendritic Cells for Expanding Antigen-Specific T Cells used in Cancer Immunotherapy
Klechevsky, Eynav ; Pathak, Amit ; Sarker, Bapi
T-017391

— Technology Description: A team led by Drs. Amit Pathak and Eynav Klechevsky have developed a soft alginate-gelatin matrix-based synthetic dendritic cell to rapidly expand and deliver CD8+ T cells for cancer immunotherapy. CD8+ T cells kill tumors, but current methods to expand them also activate r…

Selective RANK ligand to treat osteoporosis
Fremont, Daved ; Nelson, Christopher ; Teitelbaum, Steven ; Warren, Julia
T-014404

— Disease indication – Osteoporosis, skeletal metastasis, and potentially rheumatoid arthritis, psoriasis, acute myeloid leukemia, and breast cancer Drug format – Engineered Protein Research stage and Preliminary data – Proof of concept in vitro and in vivo Target – Receptor A…

Exosome-based therapy for tendon injuries and other soft tissue repair
Shen, Hua
T-018565

— Technology Description: A team of researchers at Washington University has developed a cell-free, nano-sized extracellular vesicle (EV/exosome) system to enhance repair of soft musculoskeletal tissue. This technology leverages the natural anti-inflammatory effects of adipose-derived stem cells (ASC…

In vivo editing via targeted adenoviral vectors
Curiel, David
T-016332

— Background: Viral vectors have been used for in vivo delivery of CRISPR/Cas9. However, it’s applications have been limited by the native tropism of the viral vector. To better utilize in vivo editing, methods must be developed to accomplish efficient, selective and coordinated delivery of CRI…

IgG Monoclonal Antibodies to Enterococcus Faecalis Gelatinase
Shaikh, Nurmohammad ; Tarr, Phillip
T-011748

— Primary Inventor: Phillip I. Tarr, MD Target: GelE(mAb 8A3)Monoclonal antibodies against E. faecalis gelatinase developed as a treatment for Crohn's disease. E. faecalis secretes many proteins into the gastrointestinal enviroment – such as Gelatinase (GelE). GelE degrades several proteins including gelatin, collagin, hemoglobin, and bioactive peptides.…

Generating pancreatic beta cells from pluripotent stem cells for diabetes cell therapy or drug development
Hogrebe, Nathaniel ; Millman, Jeffrey ; Velazco-Cruz, Leonardo ; Veronese Paniagua, Daniel ; Wernes, Kristina
T-019409

— Technology Description: Researchers in Prof. Jeffrey Millman’s laboratory have developed multiple techniques for enhancing the differentiation, maturation and function of glucose-responsive, insulin-producing SC-beta cells (pancreatic beta cells made from human pluripotent stem cells). Downst…

TR3: a stabilized TRAIL timer for use as an anticancer therapeutic
Hawkins, William ; Hotchkiss, Richard ; Spitzer, Dirk
T-007646

— WUSTL Technology 007646 Technology Description Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…

High Throughput Acoustic Particle Separation
Berezin, Mikhail ; Binkley, Michael ; Meacham, John
T-017364

— Technology Description: Methods and devices used for acoustophoresis of biologics have been developed and allow for more than 10,000 fold throughput than existing acoustophoretic devices. Applications: 1. Isolation of cells in low abundance (immune cells, circulating tumor cells) from whole bloo…

Create a Collection
Creating...